<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9AC36490-01A9-4272-809C-DAC97B997BD3"><gtr:id>9AC36490-01A9-4272-809C-DAC97B997BD3</gtr:id><gtr:name>Nu Vision Ophthalmics Limited</gtr:name><gtr:address><gtr:line1>SIR COLIN CAMPBELL BUILDING , TRIUMPH ROAD</gtr:line1><gtr:city>NOTTINGHAM</gtr:city><gtr:postCode>NG7 2TU</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9AC36490-01A9-4272-809C-DAC97B997BD3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>9AC36490-01A9-4272-809C-DAC97B997BD3</gtr:id><gtr:name>Nu Vision Ophthalmics Limited</gtr:name><gtr:address><gtr:line1>SIR COLIN CAMPBELL BUILDING , TRIUMPH ROAD</gtr:line1><gtr:city>NOTTINGHAM</gtr:city><gtr:postCode>NG7 2TU</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24915.0</gtr:offerGrant><gtr:projectCost>41526.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700568"><gtr:id>DCA04BB6-7A2A-4A0E-9307-D3BACABF2D64</gtr:id><gtr:title>Theagen: Transplantable Matrix for Ocular Surface Regeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700568</gtr:grantReference><gtr:abstractText>Corneal blindness has profound psychological and social consequences for sufferers and their families. For most affected people, corneal transplantation can restore vision with a 5 year graft survival rate of 74%. However 1 in 6 full thickness transplants still experience some degree of rejection, predominantly due to variable quality in the donor tissue. Many donated corneas (up to 30%) also do not reach the patient and are discarded as result of endothelial
and cellular issues. NuVision has noted this gap in the market for a clinically relevant, corneal equivalent construct for transplantation and have thus developed a human-cornea derived biocompatible matrix that can eliminate rejection problems.</gtr:abstractText><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24915</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700568</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>